Evidence map›Paper›PMID 40087802›Full record

ArticleTrials2025

Reduced anticoagulation targets in extracorporeal life support (RATE): protocol for a pre-planned secondary Bayesian analysis of the rate trial.

Olivier van Minnen, Maximilian Linde, Annemieke Oude Lansink-Hartgring, Bas van den Boogaard, Jeroen J H Bunge, Thijs S R Delnoij, Carlos V Elzo Kraemer, Marijn Kuijpers, Jacinta J Maas, Jesse de Metz and 5 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04536272 (Reduced Anticoagulation Targets in ECLS), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04536272 phase3completednot on this map

Reduced Anticoagulation Targets in ECLS (RATE)

TypeinterventionalSponsorUniversity Medical Center GroningenRan2020 to 2025Enrolled330ConditionsHeart Failure, Respiratory Failure, Extracorporeal Membrane Oxygenation, BleedingArmsHeparin, LMWH
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Olivier van MinnenDepartment of Critical Care, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. o.van.minnen@umcg.nl.
Maximilian LindeGESIS - Leibniz Institute for the Social Sciences, Cologne, Germany.
Annemieke Oude Lansink-HartgringDepartment of Critical Care, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Bas van den BoogaardDepartment of Intensive Care, OLVG, Amsterdam, The Netherlands.
Jeroen J H BungeDepartment of Intensive Care Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
Thijs S R DelnoijDepartment of Intensive Care Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
Carlos V Elzo KraemerDepartment of Intensive Care Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Marijn KuijpersDepartment of Intensive Care Medicine, Isala Clinics, Zwolle, The Netherlands.
Jacinta J MaasDepartment of Intensive Care Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Jesse de MetzDepartment of Intensive Care, OLVG, Amsterdam, The Netherlands.
Marcel van de PollDepartment of Intensive Care Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
Dinis Dos Reis MirandaDepartment of Intensive Care Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
Alexander P J VlaarDepartment of Intensive Care Medicine, Amsterdam University Medical Center, Location AMC, Amsterdam, The Netherlands.
Don van RavenzwaaijUnit of Psychometrics and Statistics, Department of Psychology, Faculty of Behavioural and Social Sciences, University of Groningen, Groningen, The Netherlands.
Walter M van den BerghDepartment of Critical Care, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe RATE trial is a three-arm non-inferiority randomized controlled trial in adult patients treated with extracorporeal membrane oxygenation (ECMO) on the effect of anticoagulation levels on mortality, hemorrhagic, and thrombotic complications. The current protocol presents the rationale and analysis plan for evaluating the primary and secondary outcomes under the Bayesian framework.

methodsThis protocol was drafted and submitted before study completion and, thus, the primary analysis. The primary outcome of the Bayesian analysis is mortality at 6 months. The secondary outcomes are severe hemorrhagic and thrombotic complications. We will use an uninformative prior for the primary analysis. Sensitivity analyses will be performed using a skeptical prior and an evidence-based informative prior.

conclusionThe proposed secondary, pre-planned Bayesian analysis of the RATE trial will provide additional information on the effect of different anticoagulation strategies during ECMO on complication rates. This additional Bayesian analysis will likely increase the validity of our results and complement the interpretation of the primary and several secondary outcomes.

trial registrationThis trial is registered at https://clinicaltrials.gov/ (NCT04536272), registration date September 2, 2020. This trial is also registered at the Dutch trial register (NL7976).

Indexed as

AnticoagulantsBlood CoagulationExtracorporeal Membrane OxygenationThrombosisBayes TheoremEquivalence Trials as TopicHemorrhageHumansTime FactorsTreatment OutcomeAnticoagulants

Identifiers

PMID40087802
PMCPMC11909967

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.